Narcolepsy - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Narcolepsy - Pipeline Review, H2 2018’, provides an overview of the Narcolepsy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Narcolepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Narcolepsy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Narcolepsy

- The report reviews pipeline therapeutics for Narcolepsy by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Narcolepsy therapeutics and enlists all their major and minor projects

- The report assesses Narcolepsy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Narcolepsy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Narcolepsy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Narcolepsy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Avadel Pharmaceuticals Plc

Bioprojet SCR

Evotec AG

F. Hoffmann-La Roche Ltd

H.A.C. Pharma

Heptares Therapeutics Ltd

Jazz Pharmaceuticals Plc

Ono Pharmaceutical Co Ltd ...

Avadel Pharmaceuticals Plc

Bioprojet SCR

Evotec AG

F. Hoffmann-La Roche Ltd

H.A.C. Pharma

Heptares Therapeutics Ltd

Jazz Pharmaceuticals Plc

Ono Pharmaceutical Co Ltd

OptiNose US Inc

SK Biopharmaceuticals Co Ltd

Taisho Pharmaceutical Holdings Co Ltd

Takeda Pharmaceutical Co Ltd

Theranexus SAS

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Narcolepsy – Overview

Narcolepsy – Therapeutics Development

Pipeline Overview

Pipeline by Companies ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Narcolepsy – Overview

Narcolepsy – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Narcolepsy – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Narcolepsy – Companies Involved in Therapeutics Development

Avadel Pharmaceuticals Plc

Bioprojet SCR

Evotec AG

F. Hoffmann-La Roche Ltd

H.A.C. Pharma

Heptares Therapeutics Ltd

Jazz Pharmaceuticals Plc

Ono Pharmaceutical Co Ltd

OptiNose US Inc

SK Biopharmaceuticals Co Ltd

Taisho Pharmaceutical Holdings Co Ltd

Takeda Pharmaceutical Co Ltd

Theranexus SAS

Narcolepsy – Drug Profiles

(flecainide acetate + modafinil) – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

arbaclofen – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JZP-258 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JZP-386 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JZP-507 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mazindol – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mazindol – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-4127 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OPN-021 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pentylenetetrazol – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pitolisant – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RO-5256390 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLS-010 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Orexin Receptor 2 for Narcolepsy – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Orexin-2 for Narcolepsy and Sleep Disorders – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium oxybate – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium oxybate ER – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solriamfetol hydrochloride – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVNG-3031 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-925 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TS-091 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XW-10172 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XW-10282 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YNT-185 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Narcolepsy – Dormant Projects

Narcolepsy – Discontinued Products

Narcolepsy – Product Development Milestones

Featured News & Press Releases

Sep 10, 2018: XW Labs appoints clinical development veteran Dr. Daniel Canafax as Chief Medical Officer

Sep 05, 2018: Harmony Biosciences to present data on its investigational product, Pitolisant, at upcoming International Narcolepsy Symposium

Jun 27, 2018: Jazz Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Xyrem (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients

Jun 03, 2018: Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data for Xyrem (sodium oxybate) in Pediatric Patients with Narcolepsy with Cataplexy

Jun 03, 2018: Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data from Phase 3 TONES 5 Study of Solriamfetol for Excessive Sleepiness in Narcolepsy or Obstructive Sleep Apnea

Jun 01, 2018: Suven Life Sciences participating at Sleep 2018 at Baltimore, MD. USA

May 31, 2018: Harmony Biosciences to Present Data On Its Investigational Product, Pitolisant, At Upcoming SLEEP Annual Meeting

May 22, 2018: Bioprojet: Pitolisant Progresses Towards the U.S. Market

May 21, 2018: Harmony Biosciences Receives Breakthrough Therapy And Fast Track Designations For Pitolisant

May 10, 2018: Jazz Pharmaceuticals to Present Data on Sodium Oxybate at SLEEP 2018 Annual Meeting

May 10, 2018: Jazz Pharmaceuticals to Present Data on Solriamfetol at SLEEP 2018 Annual Meeting

May 01, 2018: Jazz Pharmaceuticals Submits Supplemental New Drug Application for Xyrem (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients

Mar 22, 2018: AOP Orphan will distribute Wakix (pitolisant) from Bioprojet Pharma in Austria, Nordic countries and Central Eastern Europe

Mar 12, 2018: XW Labs Initiates First-in-Human Phase I Study for Novel Narcolepsy Treatment

Mar 02, 2018: Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Narcolepsy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Tables

Number of Products under Development for Narcolepsy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Narcolepsy – Pipeline by Avadel Pharmaceuticals Plc, H2 2018

Narcolepsy – Pipeline by Bioprojet SCR, H2 2018

Narcolepsy – Pipeline by Evotec AG, H2 2018

Narcolepsy – Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Narcolepsy – Pipeline by H.A.C. Pharma, H2 2018

Narcolepsy – Pipeline by Heptares Therapeutics Ltd, H2 2018

Narcolepsy – Pipeline by Jazz Pharmaceuticals Plc, H2 2018

Narcolepsy – Pipeline by Ono Pharmaceutical Co Ltd, H2 2018

Narcolepsy – Pipeline by OptiNose US Inc, H2 2018

Narcolepsy – Pipeline by SK Biopharmaceuticals Co Ltd, H2 2018

Narcolepsy – Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2018

Narcolepsy – Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018

Narcolepsy – Pipeline by Theranexus SAS, H2 2018

Narcolepsy – Dormant Projects, H2 2018

Narcolepsy – Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Narcolepsy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by ...

List of Figures

Number of Products under Development for Narcolepsy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports